Compare SDA & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SDA | SERA |
|---|---|---|
| Founded | 2007 | 2008 |
| Country | China | United States |
| Employees | 544 | N/A |
| Industry | Blank Checks | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.4M | 75.2M |
| IPO Year | N/A | 2021 |
| Metric | SDA | SERA |
|---|---|---|
| Price | $0.78 | $1.84 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $4.75 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 46.2K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | $12.01 | $554.81 |
| Revenue Next Year | $15.55 | $517.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5.19 |
| 52 Week Low | $0.47 | $1.56 |
| 52 Week High | $2.93 | $4.09 |
| Indicator | SDA | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 41.52 | 43.98 |
| Support Level | $0.72 | $1.61 |
| Resistance Level | $2.18 | $2.40 |
| Average True Range (ATR) | 0.14 | 0.17 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 9.52 | 19.01 |
SunCar Technology Group Inc operates digital automotive aftersales market service platform and vehicle insurance technology platform. It develops and operates online platforms that connect drivers in China with a range of aftermarket automotive services and insurance coverage options from a nationwide network of service providers. These comprehensive digital systems are built on SunCar's multi-tenant, cloud-based platform. Revenues from its continuing operations are mainly generated from providing auto eInsurance services, technology services, and auto services.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.